Sanofi acquires Cambridge mRNA startup for $470M

The French pharmaceutical giant has acquired Tidal Therapeutics, a startup developing nanoparticles that deliver genetic instructions to reprogram immune cells with messenger RNA, or mRNA. Although Tidal is still in the preclinical stage and does not yet have a website, its price tag was high: Sanofi paid $160 million up front for the startup, with up to $310 million more in milestone payments.